An interventional study of Provide ITNs at RTS,S-4 visit and Community Health Promoters identify and refer under-vaccinated children to health facilities in Malaria Vaccine, sponsored by Kenya Medical Research Institute. Completed at 1 site in Kenya. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Kenya Medical Research Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Malaria with a site in Kenya — 7 open to participants now, 10 under way, 2 of them phase 3. Malaria · Kenya.
Among the 95 studies in Malaria with a site in Kenya, this one is the 22nd largest by enrollment of the 81 interventional ones that give a count, is one of 4 that started in 2025, is one of 27 with no phase, and was the 95th registered.
1,186 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →7 of the 95 studies in Malaria with a site in Kenya are open now. Recruiting first, the newest first:
Nicole Stoffel · Sites in Kenya
Ages 6 mo–6 mo
Liverpool School of Tropical Medicine · Sites in Kenya, Burkina Faso, Mali
Ages 16+ · Women only
Novartis Pharmaceuticals · Sites in Kenya, Burkina Faso, Côte D'Ivoire and 3 more countries
Ages 2–100
Liverpool School of Tropical Medicine · Sites in Kenya
Ages 16–40 · Women only · Healthy volunteers
Kintampo Health Research Centre, Ghana · Sites in Kenya, Ghana, Malawi
Ages 6 mo–59 mo
A study can be open while its sites in Kenya have not opened yet or have stopped. Only those recruiting at a site in Kenya →
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 16 · Phase 3 24 · Phase 4 11
First in 2002; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,346 is above the median of 252 across 939 interventional studies indexed under Malaria.
Median enrollment 600 across the 81 interventional studies, 1,500 across the 14 observational. Of the 79 that completed or were terminated, 22 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 95 have an industry lead sponsor. The 10 most frequent:
Kenya Medical Research Institute is the lead sponsor of 14 studies on the registry; 1 is open to participants now.
Kenya Medical Research Institute has 3 studies filed under Malaria — fewer than ten, so there is no comparison to draw.
1 of the studies in Malaria with a site in Kenya that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05934318Liverpool School of Tropical MedicineL-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Malaria with a site in Kenya, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will identify and evaluate innovative approaches to leverage malaria vaccine visits as opportunities to enhance the delivery of other child health services in Rarieda sub-county, Siaya County, Kenya where RTS,S became part of their routine childhood immunization programs in 2019. Using a human-centred design approach, the implementation research will be conducted in two phases.
Phase 1 (Diagnose and Design) will consist of formative research to understand current practices, barriers, and facilitators for childhood health and malaria interventions using the WHO's behavioural and social drivers' framework for immunization. Having identified the barriers and facilitators to uptake, the investigators will prioritize drivers and develop innovations for implementation in collaboration with communities, healthcare workers and managers.
Phase 2 (Implement and Evaluate) will focus on implementing and evaluating the innovations developed in Phase 1. Using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) Framework, the study will assess the extent to which the interventions reach the target population, effectiveness of leveraging the malaria vaccine to increase uptake of other child health interventions, the extent of adoption by key stakeholders, and the fidelity and quality of implementation. The investigators will also explore cost and long-term sustainability.
The study will employ a mixed-methods approach, leveraging quantitative and qualitative data from health facility records, surveys, interviews, and observations.
The investigators will generate evidence on leveraging malaria vaccine visits and activities through: (i) innovative implementation strategies designed to maximize immunizations, child health interventions, and malaria prevention uptake; (ii) community engagement as an approach to optimize vaccine uptake and coverage; (iii) detailed qualitative data on the acceptability, perceptions, and barriers to uptake of vaccines and child health interventions; (iv) approaches to ensure access for zero-dose, under-vaccinated and underserved populations.
Primary caregivers of children eligible for malaria vaccination:
Healthcare workers involved in immunization services:
Community health promoters (CHPs):
Community members and leaders:
Health facility managers and sub-county/county/national health officials:
Leverage malaria vaccine to improve ITN access and use by providing ITNs at the 4th malaria dose visit, as well as vitamin A, deworming, MR2 and other missing vaccines
Behavioral: Provide ITNs at RTS,S-4 visit
Using malaria vaccine as an entry point, CHPs systematically identified under-vaccinated children during routine household visits and referred them to health facilities (HF), integrating immunization tracking into routine community activities.
Behavioral: Community Health Promoters identify and refer under-vaccinated children to health facilities
Facility-community linkages were strengthened through CHP engagement and mobile phone-based reminders, including SMS notifications and defaulter tracing
Behavioral: Enhanced defaulter tracing with use of mobile technology
Multi-component intervention: 1) strengthening immunizations and health services through interdepartmental collaboration; 2) improving vaccine visit awareness, preparedness, and defaulter tracing; and 3) targeted monthly community outreaches, with CHPs mobilizing caregivers of children due or overdue for vaccination.
Behavioral: Strengthening immunization systems, health services, and interdepartmental collaboration
\- At RTS,S-4 visit, health workers (HW) screen children for missing vaccinations and health services - HW provide catch-up vaccinations and services
* CHP screen households for under-vaccinated children * CHP Provide referral for immunization * HW vaccinate referred children * HW provide catch-up vaccinations and services * CHP follow up on referral completion
* HF diaries to record expected children on each date * HW record phone contacts in diaries to remind caregivers about visits (SMS or calls) * If caregivers cannot be reached, HW share contacts by SMS/WhatsApp with CHPs to trace defaulters at the house and provide referrals * HW screen \& provide catch-up vaccinations \& services
* Screening children for vaccination status at triage * HW use colored ink to better visualize return dates in home-based records * HW Screen \& provide catch-up vaccinations \& services * CHPs trace defaulters, provide \& follow up on referrals * HF diaries to record expected children on each date * HF conduct targeted community outreaches * CHP mobilize defaulters for scheduled outreaches
Reach
Vaccine coverage (%) in target populations and characteristics of vaccinated populations reached through study interventions
Time frame: Three months
Effectiveness
Percentage increase in primary (dose 1-3) and booster (4th) doses post-interventions in age-eligible children
Time frame: Three months
Adoption
Proportion of RTS,S vaccines provided concurrently with other vaccines/services.
Time frame: Three months
Implementation
Perceived feasibility of interventions by health workers, caregivers, and community. A semi-structured interview guide will be used to assess implementation experiences.
Time frame: Three months
Maintenance
Drivers of maintenance of interventions. A semi-structured interview guide will be used to elicit what it would take to continue implementing interventions beyond the study period.
Time frame: Three months
Plan to share: No — Only aggregated data is required for reports and manuscripts.
Ran from Jul 2025 to primary completion in Dec 2025, 5 months.
Of 96 non-industry interventional studies with no phase under Malaria, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 5 months is below that.
Counting every sponsor, half of 102 studies reached it within 23 months; a quarter within 8 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kenya Medical Research Institute